PFG Investments LLC Buys 9,121 Shares of Pfizer Inc. (NYSE:PFE)

PFG Investments LLC increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 4.7% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 201,261 shares of the biopharmaceutical company’s stock after purchasing an additional 9,121 shares during the period. PFG Investments LLC’s holdings in Pfizer were worth $5,824,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of PFE. Forsta AP Fonden boosted its holdings in shares of Pfizer by 10.8% during the third quarter. Forsta AP Fonden now owns 1,421,400 shares of the biopharmaceutical company’s stock worth $41,135,000 after acquiring an additional 138,800 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Pfizer by 29.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,888,282 shares of the biopharmaceutical company’s stock worth $84,020,000 after purchasing an additional 659,906 shares in the last quarter. Osborne Partners Capital Management LLC raised its position in shares of Pfizer by 0.3% in the third quarter. Osborne Partners Capital Management LLC now owns 190,699 shares of the biopharmaceutical company’s stock valued at $5,519,000 after buying an additional 520 shares in the last quarter. BKM Wealth Management LLC boosted its stake in shares of Pfizer by 97.5% in the third quarter. BKM Wealth Management LLC now owns 11,050 shares of the biopharmaceutical company’s stock valued at $320,000 after buying an additional 5,455 shares during the period. Finally, Allworth Financial LP grew its position in Pfizer by 4.4% during the third quarter. Allworth Financial LP now owns 117,755 shares of the biopharmaceutical company’s stock worth $3,408,000 after buying an additional 4,915 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on PFE. Barclays upped their target price on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. UBS Group raised their target price on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Sanford C. Bernstein started coverage on shares of Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price target for the company. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Finally, Wells Fargo & Company boosted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Eight research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and a consensus price target of $33.58.

Pfizer Trading Down 0.7 %

Shares of PFE stock traded down $0.19 during mid-day trading on Friday, reaching $28.45. 26,091,111 shares of the stock traded hands, compared to its average volume of 36,849,277. The company has a market cap of $161.22 billion, a price-to-earnings ratio of -61.85, a price-to-earnings-growth ratio of 1.01 and a beta of 0.67. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The stock’s fifty day simple moving average is $29.08 and its two-hundred day simple moving average is $28.50. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $31.54.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. During the same period last year, the company earned $0.67 EPS. The firm’s revenue was up 2.1% compared to the same quarter last year. On average, research analysts anticipate that Pfizer Inc. will post 2.67 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be paid a $0.42 dividend. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 annualized dividend and a dividend yield of 5.91%. Pfizer’s payout ratio is -365.21%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.